IMC Chicago’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.69M Buy
20,000
+5,000
+33% +$1.09M ﹤0.01% 2525
2026
Q2
$3.67M Buy
15,000
+3,600
+32% +$781K ﹤0.01% 2427
2026
Q1
$1.93M Sell
11,400
-12,200
-52% -$2.11M ﹤0.01% 2614
2025
Q4
$4.31M Buy
23,600
+10,500
+80% +$1.47M ﹤0.01% 1847
2025
Q3
$1.59M Buy
+13,100
New +$1.48M ﹤0.01% 2398

Other funds holding AXSM

IMC Chicago's AXSM Position: Q3 2026 in Review

IMC Chicago increased its Axsome Therapeutics (AXSM) stake by 58% in Q3 2026, buying an estimated $1.29M and bringing the position to 16,112 shares worth $2.97M. The position accounts for ﹤0.01% of the portfolio, ranked #2757.

IMC Chicago first reported a position in AXSM in Q1 2026 and has held it in 3 quarters since. 235 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • IMC Chicago held 16,112 shares of Axsome Therapeutics worth $2.97M as of Q3 2026.
  • IMC Chicago bought 5,925 Axsome Therapeutics shares in Q3 2026, an estimated $1.29M.
  • Axsome Therapeutics made up ﹤0.01% of IMC Chicago's portfolio in Q3 2026, its #2757 holding.
  • IMC Chicago first reported a position in Axsome Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 235 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on IMC Chicago's 13F filing for Q3 2026, filed 5 Nov 2026.